Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells

References

• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57–70.
   PubMed Web of Science ®Google Scholar
• Seger R, Yarden Y, Kashles O, Goldblatt D, Schlessinger J, Shaltiel S. The epidermal growth factor receptor as a substrate for a kinase-splitting membranal proteinase. J Biol Chem 1988;263(7):3496–500.
   Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev 2005;5(5):341–54.
   Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 2000;19(13):3159–67.
   PubMedGoogle Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2(2):127–37.
   PubMed Web of Science ®Google Scholar
• Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49–139.
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489–501.
   PubMed Web of Science ®Google Scholar
• Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 1998;67:481–507.
   PubMed Web of Science ®Google Scholar
• Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004;44:195–217.
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366(1):2–16.
   Google Scholar
• Saba NF, Khuri FR, Shin DM.Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology (Williston Park) 2006;20(2):153–61; discussion 62, 66, 69 passim.
   Google Scholar
• Khuri FR, Cohen V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res 2004;10(12 Pt 2):4249s–53s.
   Google Scholar
• Harichand-Herdt S, Ramalingam SS. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. Semin Thorac Cardiovasc Surg 2008;20(3):217–23.
   Google Scholar
• Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90(11):824–32.
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350–6.
   PubMed Web of Science ®Google Scholar
• Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 2007;8 Suppl 2:S79–85.
   Google Scholar
• Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006;20(5 Suppl 2):15–25.
   Google Scholar
• Sattler M, Abidoye O, Salgia R. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal 2008;8:909–19.
   Google Scholar
• Xi B, Yu N, Wang X, Xu X, Abassi YA. The application of cell-based label-free technology in drug discovery. Biotechnol J 2008;3(4):484–95.
   Google Scholar
• Fang Y. Label-free cell-based assays with optical biosensors in drug discovery. Assay Drug Dev Technol 2006;4(5): 583–95.
   Google Scholar
• Fang Y, Ferrie A, Fontaine N, Ki Yuen P. Optical biosensors for monitoring dynamic mass redistribution in living cells mediated by epidermal growth factor receptor activation. Conf Proc IEEE Eng Med Biol Soc 2005;1:666–9.
   Google Scholar
• Fang Y, Ferrie AM, Fontaine NH, Mauro J, Balakrishnan J. Resonant waveguide grating biosensor for living cell sensing. Biophys J 2006;91(5):1925–40.
   Google Scholar
• Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4(2):67–73.
   PubMed Web of Science ®Google Scholar
• Fang Y, Ferrie AM, Fontaine NH, Yuen PK. Characteristics of dynamic mass redistribution of epidermal growth factor receptor signaling in living cells measured with label-free optical biosensors. Anal Chem 2005;77(17):5720–5.
   Google Scholar
• Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res 1996;56(15):3540–5.
   Google Scholar
• Kamath S, Buolamwini JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev 2006;26(5):569–94.
   Google Scholar
• Fang Y, Ferrie AM, Li G. Probing cytoskeleton modulation by optical biosensors. FEBS Lett 2005;579(19):4175–80.
   Google Scholar
• Bernier J, Schneider D. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer 2007;43(1):35–45.
   Google Scholar
• Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys 2004;58(3):991–1002.
   Google Scholar
• Muller S, Su L, Tighiouart M, et al. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation. Cancer 2008;113(1):97–107.
   Google Scholar
• Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62(20):5749–54.
   Google Scholar
• Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57(21):4838–48.
   Google Scholar
• Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14(3):295–304.
   Google Scholar
• Taguchi T, Tsukuda M, Imagawa-Ishiguro Y, Kato Y, Sano D. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncol Rep 2008;19(1):65–71.
   Google Scholar